Edoxaban in patients with atrial fibrillation

Alon Eisen, Christian T. Ruff*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Edoxaban, a direct factor Xa inhibitor, was extensively studied in the prevention and treatment of venous thromboembolism and in patients with nonvalvular atrial fibrillation (AF). The aim of this review is to focus specifically on the efficacy and safety profile of edoxaban in patients with AF from preclinical development through the phase III trial that led to regulatory approval.

Original languageEnglish
Pages (from-to)81-90
Number of pages10
JournalTherapeutic Advances in Cardiovascular Disease
Issue number3
StatePublished - 1 Mar 2017
Externally publishedYes


  • Novel oral anticoagulants
  • atrial fibrillation
  • edoxaban
  • factor xa inhibitor
  • non-vitamin K oral anticoagulants


Dive into the research topics of 'Edoxaban in patients with atrial fibrillation'. Together they form a unique fingerprint.

Cite this